Whitehawk Therapeutics, Inc.

Whitehawk Therapeutics, Inc. is a U.S.-based clinical-stage oncology therapeutics company focused on developing antibody-drug conjugates and other targeted cancer medicines. The company’s portfolio centers on advanced linker-payload technology and tumor-antigen targeting programs intended for global development and commercialization.

−1 600,0 %

89,4 %

−288,3 %

−72,5 %

10.26

10.26

— Whitehawk Therapeutics, Inc.
%
ADC therapies70% Preclinical and clinical-stage antibody-drug conjugates targeting validated tumor antigens.
Legacy oncology product30% FYARRO commercialization for advanced malignant PEComa and related oncology use.

Whitehawk’s customers are oncology physicians, hospitals, and specialty distributors/pharmacies that support access to...

  • Oncology treatment centersprimary

    Hospitals, cancer centers, and physicians that prescribe and administer oncology drugs for eligible patients.

  • Specialty distribution channelprimary

    Specialty distributors and specialty pharmacies that purchase FYARRO and manage product access.

  • Patients with rare cancerssecondary

    Patients with advanced malignant PEComa and other targeted oncology indications.

  • Licensing and development partnerssecondary

    Counterparties involved in IP licensing, development milestones, and future commercialization rights.

Whitehawk is headquartered in the United States and has commercial history in the U.S. through FYARRO...

  • •Headquartered in the United States
  • •FYARRO was launched commercially in the U.S.
  • •ADC license covers global commercialization rights
  • •China-linked technology and development counterparties
  • •Future approvals may span U.S. and foreign regulators

Whitehawk’s strategy is to advance a portfolio of three next-generation ADC therapies built on the CPT113...

01
Advance the ADC portfolioshort-term

Clinical and preclinical progress is the main path to future value creation.

02
Develop and validate the CPT113 platformmedium-term

Platform performance underpins differentiation, efficacy, and partnering potential.

03
Secure and manage IP rightsmedium-term

The business depends on licensed technology and enforceable patent protection.

Whitehawk faces the typical risks of a preclinical biopharmaceutical company: uncertain clinical outcomes, regulatory...

critical

Preclinical and clinical development failure

The ADC portfolio has not yet proven itself in late-stage human studies, so efficacy and safety remain uncertain.

Scope
ADC therapies
Materiality
high
high

Capital needs and funding risk

Drug development requires sustained spending before any product can generate meaningful revenue.

Scope
Research and development programs
Materiality
high
high

Competition in ADC oncology

Large biopharma and specialty oncology companies are developing similar ADC technologies and targets.

Scope
PTK7, MUC16, SEZ6 and broader ADC market
Materiality
high
high

Dependence on third-party licensed IP

The company’s core programs rely on external patent and know-how rights that could be constrained by contract terms.

Scope
WuXi Biologics license
Materiality
high
medium

China-related operational exposure

Technology and development relationships tied to China can be affected by trade, regulatory, or supply chain disruption.

Scope
China-linked counterparties
Materiality
medium
Revenue recognition for product sales
Affects reported net product revenue and receivables
License agreement accounting
Affects operating expenses and future cash commitments
Research and development accruals
Affects quarterly R&D expense and liabilities
Stock-based compensation
Affects operating loss and diluted share metrics

Immunome Inc.

IMNM · Pharmaceutical Preparations

Foghorn Therapeutics Inc.

FHTX · Pharmaceutical Preparations

Indaptus Therapeutics, Inc.

INDP · Pharmaceutical Preparations

WINDTREE THERAPEUTICS INC /DE/

WINT · Biological Products, (No Diagnostic Substances)

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Aptevo Therapeutics Inc.

APVO · Pharmaceutical Preparations

: 29/04/2026